6/28/23, 1:21 AM Diuretics in PE Pathway Feedback Search Clinical Topics Home Studies Diuretics in PE Diuretics in PE Disease Pulmonary embolism Trial question Is diuretic therapy superior to volume expansion in patients with acute intermediate high-risk PE? Study design Multi-center Open label RCT Population 60 patients Inclusion criteria: patients with intermediate high-risk PE Key exclusion criteria: thrombolysis, cardiogenic shock, severe chronic renal impairment, pregnancy Interventions N=30 diuretic therapy (furosemide at a dose of 40 mg IV) N=30 volume expansion (isotonic sodium chloride 9%) Primary outcome Time to b-type natriuretic peptide normalization 108.0 hours 108 81.0 hours 56 54.0 hours 27.0 hours No significant difference 0.0 hours https://web.pathway.md/studies/recEXLpUReoqcKaut 1/2 6/28/23, 1:21 AM Diuretics in PE Pathway Diuretic therapy Volume expansion No significant difference in time to b-type natriuretic peptide normalization (56 hours vs. 108 hours; AD -52 hours, 95% CI -104.09 to 0.09) Secondary outcomes Significant decrease in achievement of a 50% decrease in b-type natriuretic peptide from peak value (36 hours vs. 54 hours; AD -18 hours, 95% CI -29.87 to -6.13) Significant increase in b-type natriuretic peptide concentration reduction within first 12 hours (42% vs. 12%; AD 30%, 95% CI 12.2 to 47.8) Conclusion In patients with intermediate high-risk PE, diuretic therapy was superior to volume expansion with respect to time to b-type natriuretic peptide normalization. Reference Emile Ferrari, Benjamin Sartre, Mohamed Labbaoui et al. Diuretics Versus Volume Expansion in the Initial Management of Acute Intermediate High-Risk Pulmonary Embolism. Lung. 2022 Apr;200(2):179-185. Open reference URL https://web.pathway.md/studies/recEXLpUReoqcKaut 2/2